Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ALL3
MCID: LKM060
MIFTS: 56

Leukemia, Acute Lymphoblastic 3 (ALL3)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Leukemia, Acute Lymphoblastic 3

About this section

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic 3:

Name: Leukemia, Acute Lymphoblastic 3 56
Leukemia, Acute Lymphoblastic, Susceptibility to, 3 56 29 6 39 71
B-All 58 54
Precursor B-Cell Acute Lymphoblastic Leukemia/lymphoma 58
Precursor B-Cell Acute Lymphocytic Leukemia/lymphoma 58
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 71
Precursor B-Cell Acute Lymphoblastic Leukemia 58
Precursor B-Cell Acute Lymphocytic Leukemia 58
Precursor B-Cell Lymphoblastic Leukemia 71
Burkitt Lymphoma 71
All3 56

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare haematological diseases


External Ids:

OMIM 56 615545
ICD10 via Orphanet 33 C83.5 C91.0
UMLS via Orphanet 72 C0006413 C1292769
Orphanet 58 ORPHA99860
MedGen 41 C3809874
UMLS 71 C0006413 C0023485 C1292769 more
Sources

Summaries for Leukemia, Acute Lymphoblastic 3

About this section
MalaCards based summary : Leukemia, Acute Lymphoblastic 3, also known as leukemia, acute lymphoblastic, susceptibility to, 3, is related to acute t cell leukemia and leukemia, acute lymphoblastic, and has symptoms including bone pain An important gene associated with Leukemia, Acute Lymphoblastic 3 is PAX5 (Paired Box 5), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Teniposide and Polyestradiol phosphate have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Decreased viability and Decreased viability

More information from OMIM: 615545
Sources

Related Diseases for Leukemia, Acute Lymphoblastic 3

About this section

Diseases in the Leukemia, Acute Lymphoblastic family:

Leukemia, Acute Lymphoblastic 2 Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 132)
# Related Disease Score Top Affiliating Genes
1 acute t cell leukemia 32.3 TCF3 IKZF1 FLT3 CDKN2A ABL1
2 leukemia, acute lymphoblastic 31.0 TCF3 RUNX1 PBX1 PAX5 KMT2A IKZF1
3 myeloid leukemia 30.9 RUNX1 KMT2A FLT3 ETV6 BCR ABL1
4 monocytic leukemia 30.8 RUNX1 KMT2A FLT3
5 childhood acute lymphocytic leukemia 30.7 TCF3 PBX1 IKZF1 ETV6 AFF1
6 lymphocytic leukemia 30.6 RUNX1 PAX5 KMT2A IKZF1 ETV6 BCR
7 myelodysplastic syndrome 30.4 RUNX1 KMT2A FLT3 ETV6 CDKN2A ABL1
8 acute leukemia 30.4 TCF3 RUNX1 PAX5 KMT2A FLT3 ETV6
9 leukemia, chronic lymphocytic 30.3 PAX5 KMT2A IGH FLT3 CDKN2A BCR
10 b-cell lymphoma 30.2 PAX5 IKZF1 IGH FOXP1 CDKN2A BCR
11 myeloproliferative neoplasm 30.2 RUNX1 PDGFRA KMT2A FLT3 ETV6 BCR
12 b-cell adult acute lymphocytic leukemia 30.1 IKZF1 BCR ABL1
13 precursor t-cell acute lymphoblastic leukemia 30.0 KMT2A IKZF1 IGH FLT3 ETV6 CDKN2A
14 hematologic cancer 30.0 RUNX1 PAX5 KMT2A IKZF1 FLT3 ETV6
15 leukemia 29.7 TCF3 RUNX1 PBX1 PAX5 KMT2A IKZF1
16 leukemia, acute myeloid 29.4 TCF3 RUNX1 PDGFRA PBX1 PAX5 KMT2A
17 childhood leukemia 29.3 TCF3 RUNX1 PBX1 KMT2A ETV6 CDKN2A
18 leukemia, chronic myeloid 29.2 RUNX1 PDGFRA KMT2A IKZF1 FLT3 ETV6
19 ring chromosome 21 10.6 KMT2A ETV6
20 ring chromosome 10.6 KMT2A ETV6
21 philadelphia-negative chronic myeloid leukemia 10.6 BCR ABL1
22 cytogenetically normal acute myeloid leukemia 10.5 KMT2A FLT3
23 primary hypereosinophilic syndrome 10.5 PDGFRA ETV6
24 inverted transitional papilloma 10.5 GATA3 CDKN2A
25 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.5 RUNX1 FLT3
26 heart leiomyosarcoma 10.5 PDGFRA CDKN2A
27 myeloid sarcoma 10.5 PAX5 KMT2A FLT3
28 testicular leukemia 10.5 ETV6 ABL1
29 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.4 PDGFRA ETV6 ABL1
30 primary cutaneous b-cell lymphoma 10.4 PAX5 CDKN2A
31 chronic neutrophilic leukemia 10.4 KMT2A AFF1 ABL1
32 hemophagocytic lymphohistiocytosis 10.4
33 lymphoblastic lymphoma 10.4
34 cebpa-associated familial acute myeloid leukemia 10.4 RUNX1 FLT3 ETV6
35 agammaglobulinemia, non-bruton type 10.4 TCF3 IGH
36 tafro syndrome 10.4 TCF3 RUNX1
37 8p11 myeloproliferative syndrome 10.4 RUNX1 FLT3 BCR
38 central nervous system lymphoma 10.4 PAX5 FOXP1 CDKN2A
39 fibrosarcoma of bone 10.4 PDGFRA CDKN2A
40 plasmacytoma 10.4 PAX5 IGH CDKN2A
41 myelodysplastic/myeloproliferative neoplasm 10.4 KMT2A FLT3 ETV6 ABL1
42 merkel cell carcinoma 10.4 PDGFRA PAX5 CDKN2A
43 cerebellar angioblastoma 10.4 PDGFRA ETV6
44 malignant histiocytosis 10.4
45 chromosomal triplication 10.4
46 histiocytic sarcoma 10.4
47 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.4 RUNX1 KMT2A FLT3 ETV6
48 dermatofibrosarcoma protuberans 10.3 PDGFRA CDKN2A ABL1
49 lymphoma, mucosa-associated lymphoid type 10.3 PAX5 IGH FOXP1
50 chronic eosinophilic leukemia 10.3 PDGFRA FLT3 ETV6 ABL1

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic 3:



Diseases related to Leukemia, Acute Lymphoblastic 3
Sources

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic 3

About this section

Clinical features from OMIM:

615545

UMLS symptoms related to Leukemia, Acute Lymphoblastic 3:


bone pain

GenomeRNAi Phenotypes related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.99 BCR
2 Decreased viability GR00173-A 9.99 FLT3 PDGFRA
3 Decreased viability GR00221-A-1 9.99 ABL1 CDKN2A FLT3 PDGFRA PIP4K2A
4 Decreased viability GR00221-A-2 9.99 ABL1 BCR
5 Decreased viability GR00221-A-3 9.99 ABL1 CDKN2A PDGFRA
6 Decreased viability GR00221-A-4 9.99 CDKN2A FLT3 PDGFRA PIP4K2A BCR
7 Decreased viability GR00301-A 9.99 PIP4K2A BCR
8 Decreased viability GR00342-S-1 9.99 ABL1
9 Decreased viability GR00342-S-2 9.99 ABL1
10 Decreased viability GR00342-S-3 9.99 ABL1 BCR
11 Decreased viability GR00402-S-2 9.99 ABL1 CDKN2A FLT3 PDGFRA PIP4K2A BCR

MGI Mouse Phenotypes related to Leukemia, Acute Lymphoblastic 3:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.41 ABL1 AFF1 AUTS2 BCR CDKN2A ETV6
2 cellular MP:0005384 10.4 ABL1 AUTS2 BCR CDKN2A ETV6 FLT3
3 cardiovascular system MP:0005385 10.35 ABL1 AUTS2 CDKN2A ETV6 GATA3 HLF
4 hematopoietic system MP:0005397 10.34 ABL1 AFF1 BCR CDKN2A ETV6 FLT3
5 behavior/neurological MP:0005386 10.32 ABL1 AFF1 AUTS2 BCR CDKN2A HLF
6 endocrine/exocrine gland MP:0005379 10.3 ABL1 AFF1 AUTS2 CDKN2A ETV6 FLT3
7 immune system MP:0005387 10.3 ABL1 AFF1 BCR CDKN2A ETV6 FLT3
8 mortality/aging MP:0010768 10.3 ABL1 AFF1 AUTS2 BCR CDKN2A ETV6
9 homeostasis/metabolism MP:0005376 10.29 ABL1 BCR CDKN2A ETV6 FLT3 GATA3
10 embryo MP:0005380 10.24 ABL1 AUTS2 CDKN2A ETV6 GATA3 KMT2A
11 digestive/alimentary MP:0005381 10.15 ABL1 BCR CDKN2A ETV6 GATA3 IKZF1
12 liver/biliary system MP:0005370 10.1 ABL1 AUTS2 BCR CDKN2A HLF IKZF1
13 nervous system MP:0003631 10.07 ABL1 AFF1 AUTS2 BCR CDKN2A GATA3
14 neoplasm MP:0002006 10.06 AUTS2 CDKN2A ETV6 FLT3 IKZF1 KMT2A
15 integument MP:0010771 10.03 CDKN2A ETV6 GATA3 IKZF1 KMT2A PBX1
16 no phenotypic analysis MP:0003012 9.93 AFF1 AUTS2 CDKN2A ETV6 FLT3 GATA3
17 normal MP:0002873 9.73 ABL1 BCR ETV6 GATA3 HLF KMT2A
18 skeleton MP:0005390 9.32 ABL1 AUTS2 CDKN2A FLT3 GATA3 KMT2A
Sources

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic 3

About this section

Drugs for Leukemia, Acute Lymphoblastic 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 578)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Teniposide Approved Phase 4 29767-20-2 34698
2
Polyestradiol phosphate Approved Phase 4 28014-46-2
3
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
4
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
5
Ethanol Approved Phase 4 64-17-5 702
6
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
7
Methadone Approved Phase 4 76-99-3 4095
8
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
9
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
10
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
11
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
12
leucovorin Approved Phase 4 58-05-9 6006 143
13
rituximab Approved Phase 4 174722-31-7 10201696
14
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
15 Contraceptive Agents Phase 4
16 Estradiol 17 beta-cypionate Phase 4
17 Estradiol 3-benzoate Phase 4
18 Estrogens Phase 4
19 Progestins Phase 4
20 Antitubercular Agents Phase 4
21 Narcotics Phase 4
22 Analgesics, Opioid Phase 4
23 Central Nervous System Depressants Phase 4
24 Respiratory System Agents Phase 4
25 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
26 Antitussive Agents Phase 4
27 Hypolipidemic Agents Phase 4
28 Lipid Regulating Agents Phase 4
29 Narcotic Antagonists Phase 4
30 Vitamin B Complex Phase 4
31 Folic Acid Antagonists Phase 4
32 Dermatologic Agents Phase 4
33 Folate Phase 4
34 Vitamin B9 Phase 4
35 Antimetabolites Phase 4
36 Immunosuppressive Agents Phase 4
37 Antineoplastic Agents, Immunological Phase 4
38 Orange Approved Phase 3
39
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
40
Hydroxyurea Approved Phase 3 127-07-1 3657
41
Norgestrel Approved Phase 2, Phase 3 6533-00-2 13109
42
Tranexamic Acid Approved Phase 2, Phase 3 1197-18-8 5526
43
Melphalan Approved Phase 3 148-82-3 4053 460612
44
Dalteparin Approved Phase 3 9005-49-6
45
Acyclovir Approved Phase 3 59277-89-3 2022
46
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
47
Ofloxacin Approved Phase 3 82419-36-1 4583
48
Carmustine Approved, Investigational Phase 3 154-93-8 2578
49
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
50
Piperacillin Approved Phase 3 66258-76-2 43672

Interventional clinical trials:

(show top 50) (show all 887)
# Name Status NCT ID Phase Drugs
1 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
2 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
3 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
4 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
5 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
6 Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
7 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
8 Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone Completed NCT01940653 Phase 4 Progesterone
9 A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE Recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
10 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
11 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
12 Timed Intercourse Versus Intrauterine Insemination in Infertile Patients Undergoing Gonadotropin Ovarian Stimulation Suspended NCT00502281 Phase 4 highly purified urinary FSH
13 Efficacy of MabThera in Patients With Rheumatoid Arthritis, by Measurement of Disease Parameters Through Magnetic Resonance of the Hand (RESONAR Study) Terminated NCT01117129 Phase 4 rituximab [MabThera/Rituxan];placebo;methotrexate;rituximab [Mabthera/Rituxan]
14 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3 rituximab
15 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
16 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
17 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
18 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
19 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
20 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
21 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
22 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
23 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
24 Is Early Preparation With GnRh Agonists Injection on D-1 of Menses of Hormonal Replacement Cycle Improves Pregnancy Rate in Women With Impaired Ovulation and Undergoing Frozen-Thawed Embryo Transfer? A Randomized Controlled Study Unknown status NCT03353883 Phase 2, Phase 3 Triptorelin SR
25 A Double-bline Safety and Efficacy Study Comparing Pad-gauze With Tranexamic Acid (Hemostopanâ„¢) to a Regular Pad-gauze in Controlling Bleeding in Patients on Hemodialysis. Unknown status NCT01854476 Phase 2, Phase 3
26 PROSPECTIVE CONTROLLED STUDY FOR THE OPTIMIZATION OF THERAPY IN CHRONIC MYELOID LEUKEMIA (CML): MULTICENTRIC STUDY FOR THE EVALUATION OF INTERFERON ALPHA VS ALLOGENIC BM TRANSPLANTATION WITH CHEMOTHERAPY IN CML Unknown status NCT00002771 Phase 3 busulfan;cytarabine;hydroxyurea;idarubicin
27 A Pilot Study of Dose Intensification of Methotrexate in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Cell Non-Hodgkins Lymphoma and B-Cell All Completed NCT00005977 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;vincristine sulfate
28 A RANDOMIZED PROSPECTIVE TRIAL OF CHOP VERSUS MCOP IN ELDERLY PATIENTS WITH INTERMEDIATE AND HIGH GRADE NON-HODGKIN'S LYMPHOMA (AGED 65 YEARS AND OVER) Completed NCT00002576 Phase 3 cyclophosphamide;doxorubicin hydrochloride;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
29 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
30 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
31 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
32 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
33 Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study] Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
34 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
35 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
36 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
37 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
38 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
39 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
40 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
41 SWOG-9704 A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant) for Patients With Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups Completed NCT00004031 Phase 3 CHOP regimen;carmustine;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
42 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
43 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
44 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
45 Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study] Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
46 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
47 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
48 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
49 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
50 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic 3

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cyclophosphamide
Sources

Genetic Tests for Leukemia, Acute Lymphoblastic 3

About this section

Genetic tests related to Leukemia, Acute Lymphoblastic 3:

# Genetic test Affiliating Genes
1 Leukemia, Acute Lymphoblastic, Susceptibility to, 3 29 PAX5
Sources

Anatomical Context for Leukemia, Acute Lymphoblastic 3

About this section

MalaCards organs/tissues related to Leukemia, Acute Lymphoblastic 3:

40
B Cells, T Cells, Bone, Bone Marrow, Myeloid, B Lymphoblasts, Breast
Sources

Publications for Leukemia, Acute Lymphoblastic 3

About this section

Articles related to Leukemia, Acute Lymphoblastic 3:

(show top 50) (show all 6036)
# Title Authors PMID Year
1
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. 61 56 6
24013638 2013
2
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. 61 56
30643249 2019
3
Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. 54 61
20160164 2010
4
[Prognostic significance of TEL/AML1 rearrangement and its additional genetic changes in Korean childhood precursor B-acute lymphoblastic leukemia]. 54 61
20197715 2010
5
ABL1 gene deletion without BCR/ABL1 rearrangement in a young adolescent with precursor B-cell acute lymphoblastic leukemia: clinical study and literature review. 54 61
20082857 2010
6
Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker. 54 61
20023257 2010
7
Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study. 54 61
19837270 2009
8
[Characteristics of fusion gene and immunophenotype in MLL gene rearrangement positive childhood acute lymphoblastic leukemia]. 54 61
19840468 2009
9
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. 54 61
18923441 2009
10
Very early onset of an acute myeloid leukemia in an adult patient with B-cell lymphoblastic leukemia. 54 61
19143872 2009
11
[Gene expression profile of human TGF-beta signal transduction pathway of B cell type acute lymphocytic leukemia]. 54 61
18718051 2008
12
Frequent but nonrandom expression of myeloid markers on de novo childhood acute lymphoblastic leukemia. 54 61
17434163 2007
13
[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. 54 61
17430665 2007
14
Immunophenotypic subtyping of leukemic cells from Iranian patients with acute lymphoblastic leukaemia: association to disease outcome. 54 61
17652839 2007
15
CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells. 54 61
17082584 2006
16
Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study. 54 61
16938666 2006
17
Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. 54 61
16939815 2006
18
Chemokine receptor expression and function in childhood acute lymphoblastic leukemia of B-lineage. 54 61
16118018 2006
19
[Expression of the transcription factor PAX5 in childhood acute leukemic cells]. 54 61
16584581 2006
20
Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18). 54 61
16809887 2006
21
Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with acute lymphoblastic leukemia. 54 61
16234090 2005
22
[Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry]. 54 61
16185473 2005
23
Interphase FISH to detect PBX1/E2A fusion resulting from the der(19)t(1;19)(q23;p13.3) or t(1;19)(q23;p13.3) in paediatric patients with acute lymphoblastic leukaemia. 54 61
15801954 2005
24
[CXCR4 expression in B-lineage acute lymphocyte leukemia and its significance]. 54 61
15363127 2004
25
PEG10 activation by co-stimulation of CXCR5 and CCR7 essentially contributes to resistance to apoptosis in CD19+CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia. 54 61
16225771 2004
26
Mature B-cell acute lymphoblastic leukemia with t(9;11) translocation: a distinct subset of B-cell acute lymphoblastic leukemia. 54 61
15098014 2004
27
[Analysis of immunophenotype of B-lineage acute lymphoblastic leukemia cells by 4-color flow cytometry]. 54 61
12744734 2003
28
[Immunophenotypic features of bcr/abl fusion transcript-positive B-lineage acute lymphoblast leukemia]. 54 61
12744735 2003
29
Analysis of p16 gene mutations and deletions in childhood acute lymphoblastic leukemias. 54 61
12870051 2003
30
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. 54 61
12393484 2003
31
Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones. 54 61
11697497 2001
32
Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones. 54 61
11699224 2001
33
Loss of p73 gene expression in lymphoid leukemia cell lines is associated with hypermethylation. 54 61
11337015 2001
34
Differential expression of chemokine receptors in B cell malignancies. 54 61
11368435 2001
35
Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. 54 61
11237064 2001
36
Shifts in expression of immunological cell markers in relapsed acute leukemia. 54 61
11583283 2001
37
[Classification of acute leukemias according to the first latin-american consensus conference for the immunophenotyping of leukemias]. 54 61
11195181 2000
38
Expression of adhesion molecules in childhood B-lineage-cell neoplasms. 54 61
10979212 2000
39
Acute lymphoblastic leukaemia: correlation between morphological/immunohistochemical and molecular biological findings in bone marrow biopsy specimens. 54 61
10889907 2000
40
Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia. 54 61
10634644 2000
41
[Homozygous deletion and methylation of p16 and p15 gene in acute leukemia]. 54 61
11721412 1999
42
Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. 54 61
10419905 1999
43
p16/MTS1/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation. 54 61
10360377 1999
44
Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. 54 61
10233379 1999
45
Myeloperoxidase gene expression in infant leukemia: a Pediatric Oncology Group Study. 54 61
9638984 1998
46
Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia. 54 61
9399648 1997
47
Comparison of the effects of AcSDKP, thymosin beta4, macrophage inflammatory protein 1alpha and transforming growth factor beta on human leukemic cells. 54 61
9477130 1997
48
C-kit receptors in childhood malignant lymphoblastic cells. 54 61
9168431 1997
49
Application of long PCR to detect t(8;14)(q24;q32) translocations in childhood Burkitt's lymphoma and B-ALL. 54 61
9187426 1997
50
Coexpression of cell-surface immunoglobulin (sIg), terminal deoxynucleotidyl transferase (TdT) and recombination activating gene 1 (RAG-1): two cases and derived cell lines. 54 61
8683996 1996
Sources

Variations for Leukemia, Acute Lymphoblastic 3

About this section

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic 3:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PAX5 NM_016734.3(PAX5):c.547G>A (p.Gly183Ser)SNV risk factor 88892 rs398123063 9:37002702-37002702 9:37002705-37002705
2 PAX5 NM_016734.3(PAX5):c.1013-1G>ASNV Uncertain significance 517139 rs1554646594 9:36846927-36846927 9:36846930-36846930
3 PAX5 NM_016734.3(PAX5):c.1013-6A>GSNV Likely benign 802486 9:36846932-36846932 9:36846935-36846935
Sources

Expression for Leukemia, Acute Lymphoblastic 3

About this section
Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic 3.
Sources

Pathways for Leukemia, Acute Lymphoblastic 3

About this section

Pathways related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 36
Show member pathways
 12.48 RUNX1 PDGFRA FLT3 CDKN2A BCR ABL1
2
Pathways in cancer 36
12.36 RUNX1 PDGFRA FLT3 CDKN2A BCR ABL1
3
MicroRNAs in cancer 36
12.25 PDGFRA FOXP1 CDKN2A ABL1
4
NF-kappaB Signaling 4
11.95 TCF3 RUNX1 PBX1 PAX5 IKZF1 GATA3
5
Tyrosine Kinases / Adaptors 4
11.79 PDGFRA FLT3 BCR ABL1
6
Glioblastoma Multiforme 63
11.65 TCF3 PDGFRA CDKN2A
7
Transcriptional misregulation in cancer 36
11.49 TCF3 RUNX1 PBX1 PAX5 KMT2A FLT3
8
Innate Lymphoid Cell Differentiation Pathways 64
11.48 RUNX1 IKZF1 GATA3
9
Ponatinib Pathway, Pharmacokinetics/Pharmacodynamics 60
Show member pathways
 11.26 PDGFRA BCR ABL1
Sources

GO Terms for Leukemia, Acute Lymphoblastic 3

About this section

Cellular components related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.97 TCF3 RUNX1 PIP4K2A PDGFRA PBX1 PAX5
2 nuclear chromatin GO:0000790 9.56 TCF3 RUNX1 PBX1 PAX5 HLF GATA3
3 nucleus GO:0005634 9.55 TCF3 RUNX1 PIP4K2A PDGFRA PBX1 PAX5

Biological processes related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.97 TCF3 RUNX1 KMT2A GATA3 CDKN2A
2 phosphorylation GO:0016310 9.91 PIP4K2A PDGFRA FLT3 CDKN2A BCR ABL1
3 regulation of transcription, DNA-templated GO:0006355 9.9 TCF3 RUNX1 PBX1 PAX5 KMT2A HLF
4 transcription by RNA polymerase II GO:0006366 9.85 PAX5 KMT2A HLF GATA3
5 protein autophosphorylation GO:0046777 9.71 PDGFRA FLT3 BCR ABL1
6 positive regulation of endothelial cell migration GO:0010595 9.63 GATA3 FOXP1 ABL1
7 positive regulation of histone H3-K4 methylation GO:0051571 9.56 KMT2A AUTS2
8 hematopoietic stem cell proliferation GO:0071425 9.54 RUNX1 ETV6
9 thymus development GO:0048538 9.54 PBX1 GATA3 ABL1
10 cell activation GO:0001775 9.52 PDGFRA GATA3
11 regulation of B cell receptor signaling pathway GO:0050855 9.51 RUNX1 PAX5
12 platelet-derived growth factor receptor signaling pathway GO:0048008 9.5 PDGFRA BCR ABL1
13 negative regulation of ubiquitin-protein transferase activity GO:0051444 9.49 CDKN2A ABL1
14 lymphocyte differentiation GO:0030098 9.48 IKZF1 FLT3
15 embryonic hemopoiesis GO:0035162 9.43 PBX1 KMT2A GATA3
16 positive regulation of transcription by RNA polymerase II GO:0045944 9.4 TCF3 RUNX1 PBX1 PAX5 KMT2A IKZF1
17 regulation of hematopoietic stem cell differentiation GO:1902036 9.35 TCF3 RUNX1 KMT2A GATA3 ABL1

Molecular functions related to Leukemia, Acute Lymphoblastic 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.41 TCF3 RUNX1 PDGFRA PBX1 PAX5 KMT2A
2 DNA binding GO:0003677 9.93 TCF3 RUNX1 PBX1 PAX5 KMT2A IKZF1
3 kinase activity GO:0016301 9.88 PIP4K2A PDGFRA FLT3 CDKN2A BCR ABL1
4 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.8 TCF3 RUNX1 PBX1 PAX5 GATA3 ETV6
5 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.77 RUNX1 PBX1 HLF GATA3 ETV6
6 transcription regulatory region DNA binding GO:0044212 9.76 RUNX1 KMT2A IKZF1 GATA3
7 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.73 RUNX1 PBX1 PAX5 HLF GATA3 ETV6
8 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.65 TCF3 RUNX1 PBX1 PAX5 KMT2A IKZF1
9 vascular endothelial growth factor-activated receptor activity GO:0005021 9.43 PDGFRA FLT3
10 DNA-binding transcription factor activity GO:0003700 9.36 TCF3 RUNX1 PBX1 PAX5 KMT2A IKZF1
Sources

Sources for Leukemia, Acute Lymphoblastic 3

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....